In summary, for the current classification of AD, phases of Aβ deposition, including the appearance of neuritic plaques, and stages of neurofibrillary degeneration (tau pathology) have to be documented together with the presence and stages of different types of CAA. This evidence concerns the gene MAPT and Alzheimer disease.